RTI Surgical Inc  

(Public, NASDAQ:RTIX)   Watch this stock  
Find more results for RTIX
2.99
+0.04 (1.36%)
Real-time:   1:31PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.92 - 3.06
52 week 2.85 - 7.48
Open 2.94
Vol / Avg. 78,432.00/254,975.00
Mkt cap 172.20M
P/E 21.47
Div/yield     -
EPS 0.14
Shares 57.79M
Beta 1.24
Inst. own 79%
Feb 16, 2016
Q4 2015 RTI Surgical Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 16, 2016
Q4 2015 RTI Surgical Inc Earnings Call - 8:30AM EST - Add to calendar
Jan 8, 2016
Preliminary Q4 2015 RTI Surgical Inc Earnings Release
Nov 16, 2015
RTI Surgical Inc at Brean Capital Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 5.26% 1.03%
Operating margin 8.98% 2.14%
EBITD margin - 9.89%
Return on average assets 3.70% 0.72%
Return on average equity 6.08% -0.25%
Employees 1,102 -
CDP Score - -

Address

11621 Research Cir
ALACHUA, FL 32615-6825
United States - Map
+1-386-4188888 (Phone)
+1-386-4180342 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

RTI Surgical, Inc. produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company uses natural tissues, metals and synthetics process to produce its products. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company's business has six categories: spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), surgical specialties and dental. The Company distributes its implants and services in all 50 states and in over 45 countries worldwide.

Officers and directors

Dean H. Bergy Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Brian K. Hutchison President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert P. Jordheim Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Caroline A. Hartill Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Roger W. Rose Jr. Executive Vice President - Tissue-Based Implants, President - RTI Donor Services
Age: 55
Bio & Compensation  - Reuters
Thomas F. Rose CPA Corporate Secretary
Bio & Compensation  - Reuters
Thomas McEachin Director
Bio & Compensation  - Reuters
Christopher R Sweeney Director
Bio & Compensation  - Reuters
Philip R. Chapman Independent Director
Age: 53
Bio & Compensation  - Reuters
Peter F. Gearen M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters